Pictet Asset Management
SMMT icon

Pictet Asset Management’s Summit Therapeutics SMMT Stock Holding History

Pictet Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Sell
1,134,299
-188,880
-14% -$3.35M 0.02% 585
2026
Q1 		$24M Sell
1,323,179
-60,596
-4% -$980K 0.03% 461
2025
Q4 		$24.4M Sell
1,383,775
-220,388
-14% -$4.15M 0.02% 485
2025
Q3 		$33.5M Sell
1,604,163
-559,710
-26% -$13.6M 0.03% 406
2025
Q2 		$45.6M Sell
2,163,873
-497,731
-19% -$11.4M 0.05% 334
2025
Q1 		$52.1M Buy
2,661,604
+1,274,357
+92% +$25.6M 0.06% 296
2024
Q4 		$24.8M Buy
1,387,247
+695,843
+101% +$13.5M 0.03% 443
2024
Q3 		$14.4M Sell
691,404
-17,219
-2% -$241K 0.02% 564
2024
Q2 		$5.53M Buy
708,623
+698,560
+6,942% +$3.77M 0.01% 766
2024
Q1 		$41.7K Buy
+10,063
New +$40K ﹤0.01% 1945

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Pictet Asset Management's SMMT Position: Q2 2026 in Review

Pictet Asset Management reduced its Summit Therapeutics (SMMT) stake by 14% in Q2 2026, selling an estimated $3.35M and leaving 1,134,299 shares worth $16.4M. The position accounts for 0.02% of the portfolio, ranked #585.

Pictet Asset Management first reported a position in SMMT in Q1 2024 and has held it in 10 quarters since. The position peaked at $52.1M in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Pictet Asset Management held 1,134,299 shares of Summit Therapeutics worth $16.4M as of Q2 2026.
  • Pictet Asset Management sold 188,880 Summit Therapeutics shares in Q2 2026, an estimated $3.35M.
  • Summit Therapeutics made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #585 holding.
  • Pictet Asset Management first reported a position in Summit Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Pictet Asset Management's Summit Therapeutics position peaked at $52.1M in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.